The inhibitory action of Bevacizumab on rat corneal neovascularization

International Journal of Ophthalmology

Volumn 8, Issue 10, 2008, Pages 1955-1958

  Jing, Guo Li ^a,b   Gao, Xiao Wei ^b   Ren, Bing ^b   Xiao, Yun ^b  

^a SHIHEZI UNIVERSITY   (China)

^b No 474 Hospital of Chinese PLA   (China)

Author keywords

Bevacizumab; Corneal neovascularization; Vascular endothelial growth factor

Indexed keywords

ALKALI; BEVACIZUMAB; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL COUNT; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; CORNEA STROMA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SLIT LAMP; WISTAR RAT;

EID: 56249134923     PISSN: 16725123     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91(9):4082-4085
2. BenEzra D, Griffin BW, Maftzir G, Sharif NA, Clark AF. Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. Invest Ophthalmol Vis Sci 1997; 38(10):1954-1962
3. Klotz O, Park JK, Pleyer U, Hartmann C, Baatz H. Inhibition of corneal neovascularization by alpha (v)-integrin antagonists in the rat. Graefe's Arch Clin Exp Ophthalmol 2000;238(1):88-93
4. Gan L, Fagerholm P, Palmblad J. Vascular endothelium growth factor (VEGF) AND its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 2004;82 (5):557-563
5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron H, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-2342
6. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90(11):1344-1349
7. Yoeruek E, Spitzer MS, Tatar O, Aisenbrey S, Bartz-Schmidt KU, Szurman P. Safety profile of bevacizumab on cultured human corneal cells. Cornea 2007;26(8):977-982
8. Manzano RP, Peyman GA, Khan P, Carvounis PE, Kiviclim M, Ren M, Lake JC, Chvez-Barrios P. Inhibition of experimental corneal neovascularization by bevacizumab(Avastin). Br J Ophthalmol 2007;91 (6):804-807
9. Bock F, K nig Y, Kruse F, Baier M, Cursiefen C. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefe's Arch Clin Exp Ophthalmol 2008;246(2):281-284
10. Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefe's Arch Clin Exp Ophthalmol 2007;245(10): 1577-1579